Prophylactic HPV vaccines : New interventions for cancer controlBARR, Eliav; SINGS, Heather L.Vaccine. 2008, Vol 26, Num 49, pp 6244-6257, issn 0264-410X, 14 p.Article

Quadrivalent Human Papillomavirus VaccineBARR, Eliav; TAMMS, Gretchen.Clinical infectious diseases. 2007, Vol 45, Num 5, pp 609-617, issn 1058-4838, 9 p.Article

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women : An evaluation from multiple analytic perspectivesINSINGA, Ralph P; DASBACH, Erik J; ELBASHA, Elamin H et al.Cancer epidemiology, biomarkers & prevention. 2007, Vol 16, Num 4, pp 709-715, issn 1055-9965, 7 p.Article

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with Rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (Ibuprofen, Diclofenac, and Nabumetone)REICIN, Alise S; SHAPIRO, Deborah; SPERLING, Rhoda S et al.The American journal of cardiology. 2002, Vol 89, Num 2, pp 204-209, issn 0002-9149Article

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in MalesGIULIANO, Anna R; PALEFSKY, Joel M; CHANG, Yen-Hwa et al.The New England journal of medicine. 2011, Vol 364, Num 5, pp 401-411, issn 0028-4793, 11 p.Article

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineJOURA, Elmar A; KJAER, Susanne K; GARCIA, Patricia et al.Vaccine. 2008, Vol 26, Num 52, pp 6844-6851, issn 0264-410X, 8 p.Article

Impact of baseline covariates on the immunogenidty of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccineGIULIANO, Anna R; LAZCANO-PONCE, Eduardo; VUOCOLO, Scott C et al.The Journal of infectious diseases. 2007, Vol 196, Num 8, pp 1153-1162, issn 0022-1899, 10 p.Article

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 l1 virus-like particle (VLP) vaccineOLSSON, Sven-Eric; VILLA, Luisa L; ANDERSSON-ELLSTROM, Agneta et al.Vaccine. 2007, Vol 25, Num 26, pp 4931-4939, issn 0264-410X, 9 p.Article

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxibKONSTAM, Marvin A; WEIR, Matthew R; REICIN, Alise et al.Circulation (New York, N.Y.). 2001, Vol 104, Num 19, pp 2280-2288, issn 0009-7322Article

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American womenPEREZ, Gonzalo; LAZCANO-PONCE, Eduardo; VUOCOLO, Scott et al.International journal of cancer. 2008, Vol 122, Num 6, pp 1311-1318, issn 0020-7136, 8 p.Article

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseasesGARLAND, Suzanne M; HERNANDEZ-AVILA, Mauricio; TADDEO, Frank J et al.The New England journal of medicine. 2007, Vol 356, Num 19, pp 1928-1943, issn 0028-4793, 16 p.Article

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenBLOCK, Stan L; NOLAN, Terry; CAVANAUGH, Paul F et al.Pediatrics (Evanston). 2006, Vol 118, Num 5, pp 2135-2145, issn 0031-4005, 11 p.Article

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineAULT, Kevin A; GIULIANO, Anna R; BARR, Eliav et al.Vaccine. 2004, Vol 22, Num 23-24, pp 3004-3007, issn 0264-410X, 4 p.Article

External Genital Human Papillomavirus Prevalence and Associated Factors Among Heterosexual Men on 5 ContinentsVARDAS, Eftyhia; GIULIANO, Anna R; LIAW, Kai-Li et al.The Journal of infectious diseases. 2011, Vol 203, Num 1, pp 58-65, issn 0022-1899, 8 p.Article

Impact of a prophylactic quadrivalent human papillomavirus (types 6,11,16,18) L1 virus-like particle vaccine in a sexually active population of North American womenBARR, Eliav; GAUSE, Christine K; BAUTISTA, Oliver M et al.American journal of obstetrics and gynecology. 2008, Vol 198, Num 3, pp 261-263, issn 0002-9378, 3 p.Article

Longitudinal Evaluation of Interobserver and Intraobserver Agreement of Cervical Intraepithelial Neoplasia Diagnosis Among an Experienced Panel of Gynecologic PathologistsBING CAI; RONNETT, Brigitte M; LIAW, Kai-Li et al.The American journal of surgical pathology. 2007, Vol 31, Num 12, pp 1854-1860, issn 0147-5185, 7 p.Article

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18VILLA, Luisa L; AULT, Kevin A; KURMAN, Robert J et al.Vaccine. 2006, Vol 24, Num 27-28, pp 5571-5583, issn 0264-410X, 13 p.Article

A controlled trial of a human papillomavirus type 16 vaccineKOUTSKY, Laura A; AULT, Kevin A; WHEELER, Cosette M et al.The New England journal of medicine. 2002, Vol 347, Num 21, pp 1645-1651, issn 0028-4793, 7 p.Article

Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle VaccineBLOCK, Stan L; BROWN, Darron R; HAIPING ZHOU et al.The Pediatric infectious disease journal. 2010, Vol 29, Num 2, pp 95-101, issn 0891-3668, 7 p.Article

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialMUNOZ, Nubia; MANALASTAS, Ricardo; BAUTISTA, Oliver et al.Lancet (British edition). 2009, Vol 373, Num 9679, pp 1949-1957, issn 0140-6736, 9 p.Article

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineFRASER, Christophe; TOMASSINI, Joanne E; LIWEN XI et al.Vaccine. 2007, Vol 25, Num 21, pp 4324-4333, issn 0264-410X, 10 p.Article

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents : A randomized controlled trialREISINGER, Keith S; BLOCK, San L; ALVAREZ, Frances B et al.The Pediatric infectious disease journal. 2007, Vol 26, Num 3, pp 201-209, issn 0891-3668, 9 p.Article

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16 : A 2-year randomized controlled clinical trialPOLAND, Gregory A; JACOBSON, Robert M; KOUTSKY, Laura A et al.Mayo Clinic proceedings. 2005, Vol 80, Num 5, pp 601-610, issn 0025-6196, 10 p.Article

Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive managementTHEROUX, Pierre; ALEXANDER, Joe JR; SAX, Frederic L et al.The American journal of cardiology. 2001, Vol 87, Num 4, pp 375-380, issn 0002-9149Article

Prevalence of and Risk Factors for Human Papillomavirus (HPV) Infection Among HIV-Seronegative Men Who Have Sex With MenGOLDSTONE, Stephen; PALEFSKY, Joel M; BROOKE MARSHALL, J et al.The Journal of infectious diseases. 2011, Vol 203, Num 1, pp 66-74, issn 0022-1899, 9 p.Article